Popular on Rezul
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control"
- For Saving Home Services Inc: Easy-Approval HVAC Financing in Toronto for Affordable Furnace
- Rainbow Property Maintenance Launches Cost-Effective, High-Quality Medical Cleaning Services
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- ®Grammy Award Winner Alex Cuba releases new single "El Día Más Triste"
- Steve Nosrat Joins The Mogharebi Group to Lead Las Vegas Office
- First-Time Homebuyers Face Challenges as Starter Homes Disappear in 2025
- Titan Pressure Washing Selected a 2024 Nextdoor Neighborhood Faves for Best Pressure Washing Service
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- Country Creek Condominium Chooses Corner Property to Manage its Picturesque Residential Community
Similar on Rezul
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
- Maryland Bill Aims to Curb Mental Health Youth Transport Abuses
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
- NC Health Official Urges Ban on Wilderness Therapy Camps Following Child's Death
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
Rezul News/10673726
JUPITER, Fla. - Rezul -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Rezul News
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Rezul News
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Rezul News
- New Estate Agency Set To Shake Up Gosforth Property Market
- Winter Weather Woes? Triple Diamond Construction Offers Free Roof Assessments for OKC Homeowners
- Lennar opens a new model home at TrailMark
- Unlock the Hidden Power of Dreams in The Lucid War Chronicles
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Rezul News
- Hardwood or Tile? A Homeowner's Guide to Choosing the Right Flooring
- Explore the "Magic of Rainbows" in the New Children's Book Series "Mila and Ally's STEMventures
- Integrity Storage Group Appoints Greg Head as Chairman of the Board
- Victoria Crossing Welcomes Corner Property Management as New Partner in Community Excellence
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on Rezul News
- Popular Senior Housing Series Continues
- RNGD Opens New Headquarters Campus, Connecting Construction Operations, Manufacturing Operations and Training Center
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- Zezgo Rent A Car has arrived In Cyprus to Improve Car Rental Options
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Kim Estes Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Fire and Rescue Statistics Highlight Ongoing Fire Risks in UK Homes
- Andre Kay Honored with Black Excellence Award by the Florida Panthers
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- RE/MAX Evergreen Welcomes New Brokers Joaquin and Rebecca Robideau
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- Summerwoods Parrish Florida - Community Open House on Sunday, February 16th from 12-2 PM
- Talent Concierge® Artists Agency and The Big Talk® Announce Game-Changing Partnership Challenging Status Quo in the Meetings Industry
- FlyBright Pilot Academy Partners with Allegiant Air to Address the Pilot Shortage
- Spacious 5-Bedroom Home on 3 Acres in Locust Grove, GA – Open House This Sunday
- BEPeterson Building Engineering Partnerships
- WonderDays: The Startup Disrupting the UK Gifting Industry
- Minnesota Real Estate Agent Promotes New Target Marketing
- RE1 Advisor Expands Services to Texas